Page last updated: 2024-08-24

lurtotecan and Ovarian Neoplasms

lurtotecan has been researched along with Ovarian Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Astrow, A; Barrett, E; Campos, S; Matulonis, U; Muggia, F; Roche, M; Rusk, J; Seiden, MV; Sivret, J	1
Barrett, E; Calvert, AH; Cameron, T; Coleman, R; Dark, GG; Eisenhauer, EA; Ellard, S; Grimshaw, R; Hamilton, M; Jayson, G; Kaye, S; Le, T; McIntosh, L; Poole, C; Swenerton, K; Trudeau, M; Vasey, P; Walsh, W	1
Brown, R; McDonald, AC	1

Trials

2 trial(s) available for lurtotecan and Ovarian Neoplasms

Article	Year
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Ovarian Neoplasms; Topotecan	2004
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Canada; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms	2005

Article

Year

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.

Gynecologic oncology, 2004, Volume: 93, Issue:1

Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Ovarian Neoplasms; Topotecan

2004

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Canada; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms

2005

Other Studies

1 other study(ies) available for lurtotecan and Ovarian Neoplasms

Article	Year
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. British journal of cancer, 1998, Volume: 78, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	1998

Article

Year

Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.

British journal of cancer, 1998, Volume: 78, Issue:6

Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53

1998